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Abstract 
Background: Atrial fibrillation (AF) is the most commonly diagnosed cardiac arrhythmia in clinical practice 
and is related to significant morbidity and mortality. AF etiology and thus, predictive biomarkers are 
currently lacking. Liver enzymes have shown a correlation to cardiovascular disease. Gamma-glutamyl 
transferase (GGT) is a liver enzyme associated with oxidative stress that is postulated to have a link to AF 
occurrence. Researchers have recently placed emphasis on discovering a potential biomarker to predict 
AF. An elevation of systemic serum GGT and the association with the risk of AF development is the area 
of interest. 
Methods: Exhaustive search of available medical literature was performed using MEDLINE-Ovid, 
MEDLINE-Pubmed, Web of Science, Google Scholar, and UpToDate. Articles were determined relevant 
based on keywords and eligibility criteria. 
Results: Nine articles were reviewed and two were deemed relevant. Two observational studies were 
assessed for quality and critically reviewed. One study found that those in the highest quintile of GGT 
levels had a 40% increased risk of AF (HR 1.44, (95% CI 1.17-1.77). Another study found that there was a 
log-linear positive association of GGT with AF risk in analyses initially adjusted for age. 
Conclusion: The two studies both indicated an elevation in GGT and may be associated as a biomarker 
for the development of AF. Further study of this correlation is indicated before this biomarker can be 
implemented in clinical practice as a screening tool for AF. 
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Abstract  
Background: Atrial fibrillation (AF) is the most commonly diagnosed cardiac 
arrhythmia in clinical practice and is related to significant morbidity and mortality. AF 
etiology and thus, predictive biomarkers are currently lacking. Liver enzymes have 
shown a correlation to cardiovascular disease. Gamma-glutamyl transferase (GGT) is a 
liver enzyme associated with oxidative stress that is postulated to have a link to AF 
occurrence. Researchers have recently placed emphasis on discovering a potential 
biomarker to predict AF. An elevation of systemic serum GGT and the association with 
the risk of AF development is the area of interest. 
Methods:  Exhaustive search of available medical literature was performed using 
MEDLINE-Ovid, MEDLINE-Pubmed, Web of Science, Google Scholar, and UpToDate. 
Articles were determined relevant based on keywords and eligibility criteria.  
Results:  Nine articles were reviewed and two were deemed relevant. Two observational 
studies were assessed for quality and critically reviewed. One study found that those in 
the highest quintile of GGT levels had a 40% increased risk of AF (HR 1.44, (95% CI 
1.17-1.77). Another study found that there was a log-linear positive association of GGT 
with AF risk in analyses initially adjusted for age.  
Conclusion:  The two studies both indicated an elevation in GGT and may be associated 
as a biomarker for the development of AF. Further study of this correlation is indicated 
before this biomarker can be implemented in clinical practice as a screening tool for AF. 
Keywords:  Atrial fibrillation, arrhythmias, liver enzymes, gamma-glutamyl transferase 
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The Association of Gamma-Glutamyl Transferase and Atrial 
Fibriallation 
BACKGROUND 
 Atrial fibrillation (AF) is the most common chronic cardiac arrthymia that affects 
approximately 9% of individuals over the age of 80, and it is projected that 5.6 million 
US adults will have AF by the year 2050.1,2 AF incidence increases with age and 
importance of detection of this arrhythmia proves to be of increased interest with the 
aging population. Those with AF are at increased risk for stroke and significant morbidity 
and mortality, due to the increased susceptibility of thrombus formation as a result of 
atrial stasis.1 Due to its prevalence, extensive knowledge of AF is vitally important to 
clinicians and researchers alike. 
The mechanism of AF is poorly understood; however, the association of 
biochemical systemic inflammation and the development of AF has gained attention by 
researchers. In the past, the biomarkers that have been studied for AF prediction include 
platelet markers and liver enzymes, such as aspartate aminotransferase (AST), alanine 
aminotransferase (AST), and gamma-glutamyl transferase (GGT). An elevation of liver 
enzymes has been shown to be associated with increased risk of cardiovascular disease, 
thus prompting researchers to investigate the association with other cardiac 
abnormalities.3 An area of focus has also been placed on specific enzymes rather than a 
generalized group that has shown a potential correlation.  
Recently, GGT has gained particular interest in the research community for its 
potential to predict the risk of AF development. GGT has been used as an indicator of 
hepatic or biliary disease and has been linked with increased oxidative stress.4 These 
particular liver enzymes are used in clinical practice to detect liver cell damage or bile 
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flow interference.5 The goal of this study is to investigate if an elevation in serum GGT is 
an appropriate predictor of the development of AF when compared to populations with a 
low to normal serum GGT. 
METHODS 
 An exhaustive search of available literature was conducted in June 2016 using the 
following research platforms: MEDLINE-Ovid, MEDLINE-Pubmed, Web of Science, 
Google Scholar, and UpToDate. Literature eligibility was determined based on keywords 
and eligibility criteria. Keywords included: gamma-glutamyl transferase, liver enzymes, 
atrial fibrillation, and arrhythmias. Studies were included if sampling from the general 
population and comparing outcomes to those with atrial fibrillation. The intervention 
assessed was a comparison to those with an elevated serum GGT to low to normal GGT. 
The outcome was AF. Animal studies and non-English language studies were excluded. 
Relevant articles were deemed reputable using Grading of Recommendation Assessment, 
Development and Evaluation (GRADE) working group guidelines.8 
RESULTS 
 The initial literature search produced 9 articles. Titles and abstracts were screened 
for eligibility based on keywords and eligibility criteria. Two articles6,7 were chosen that 
fit the eligibility criteria. The 2 articles examined adult populations initially free of atrial 
fibrillation. The level of serum GGT prior to AF development was evaluated and 
compared to those who did not develop AF in the study. One study6 evaluated men and 
women, while the other study evaluated Finnish men.7 Both studies evaluated the 
populations retrospectively.  
Alonso et al  
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 This community-based cohort study6 evaluated the association between 
circulation liver enzymes and AF incidence. The study included 9333 men and women, 
age 53-75 free of AF participating in Atherosclerosis Risk in Communities (ARIC) 
Study. The ARIC is aimed to study CVD and its risk factors. There were 15 792 men and 
women who were recruited from 4 communities in the US: Forsyth Co, NC; Jackson, 
MS; northwest suburbs of Minneapolis, MN; and Washington County, MD. A majority 
of participants in Washington County and Minneapolis sites were white. Jackson 
participants were black. Forsyth County were white and black. The study followed 
individuals from 1996-2010. 6 
 Baseline exams were conducted in 1987-89. Additional exams were conducted in 
1990-92 (visit 2), 1993-95 (visit 3), 1996-98 (visit 4), and 2011-2013 (visit 5). Liver 
enzymes were measured in plasma samples collected during visit 4, thus only participants 
that attended visit 4 were included in the analysis (n=11 656). Additional exclusion of 
participants were: participants with unavailable data on liver enzymes or other covariates, 
race other than white or black, non-whites in Minneapolis and Washington County field 
centers, prevalent AF at visit 4, missing or unreadable electrocardiogram (EKG) at 
baseline, individuals with excessive alcohol intake (28 g/day in men and 14 g/day in 
women), and those with abnormal liver enzyme levels (ALT or AST 40 U/L or GGT 
110 U/L), to avoid including individuals with liver disease. Following exclusion, 9333 
participants were eligible. 6 
 ALT, AST, and GGT samples were collected in 1996-1998 and were stored at -
70C. The samples were measured in 2010-2011 from visit 4 plasma samples using an 
Olympus AU400e automated chemistry analyzer in accordance to the manufacturer’s 
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protocol. AF diagnoses were collected from EKGs performed during study exams, 
hospital discharge diagnoses, and death certificates. A standard supine 12-lead resting 
EKG was recorded with a MAC PC Personal Cardiograph and transmitted to the ARIC 
EKG reading center for automatic coding at each study exam. All detected AF cases were 
visually reviewed by a cardiologist. 6 
  Statistical analysis was completed using Cox proportional hazard models to 
estimate liver enzyme with incident AF association, with adjustment for confounding 
variables. Initially, liver enzymes were modeled using restricted cubic splines to 
investigate the dose-response shape and liver enzymes were considered untransformed. A 
base 2 log-transformation was used to facilitate interpretation of coefficients that showed 
after transformation, hazard ratios (HR) can be interpreted as the relative increase in risk 
of AF associated with doubling of the level of serum liver enzyme. The dose-response 
analysis suggested a linear association between GGT and AF, but non-linear for ALT and 
AST. Enzymes were categorized in quintiles using the lowest risk quintile as reference. 
Those in the highest quintile of GGT levels had a 40% increased risk of AF (HR 1.44, 
95%CI 1.17-1.77, with a clear linear dose-response association (p for trend = 0.0001), 
when comparing to those in the bottom quintile of GGT levels. The HR (95%CI) for 
log2(GGT) as a continuous variable in the model was 1.27 (1.17-1.38) after adjustment 
for age, sex, race and field center, and 1.20 (1.10-1.30) after additional adjustment for 
multiple confounders. No association was found between the AST/ALT ratio and AF 
risk. 6 
 Kunutsor et al.  
 The goal of this cross-sectional study7 was to assess the associations of baseline 
and long-term GGT activity with the risk of development of AF, heart failure, and/or 
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ventricular arrhythmias. The study involved 1780 Finnish men in the Kuopio Ischaemic 
Heart Disease (KIHD) study. The mean of participants was 53 (SD:5) years. Baseline 
characteristics were obtained using a questionnaire that assessed age, alcohol 
consumption, smoking status, left ventricular hypertrophy, history of diabetes, history of 
hypertension, history of coronary heart disease, use of antihypertensives, and use of 
medication for dyslipidemia. Physical baseline measurements included body mass index, 
systolic blood pressure, diastolic blood pressure, and resting heart rate. Lipid markers 
included total cholesterol, high-density lipoprotein cholesterol, and triglycerides. 
Metabolic, inflammatory, and renal markers included fasting plasma glucose, serum 
creatinine, C-reactive protein, and estimated glomerular filtration rate.7 
Baseline GGT was taken and then repeat measurements were taken at 4 and 11 
years after baseline. The baseline loge GGT (U/L) mean in standard deviation or percent 
was 3.11 (0.63). The repeat measurements were available in a random sample 624 men, 
yielding a total of 1143 repeat measurements of GGT. There were 336 incident AF events 
(annual rate 8.93/1000 person-years at risk; 95% CI: 8.03-9.94). Baseline GGT values 
were higher in men with diabetes compared to men without diabetes, higher in men with 
a history of hypertension compared to men without a history of hypertension and higher 
in current smokers compared to non-smokers. There was a log-linear positive association 
of GGT with AF risk in analyses initially adjusted for age. The regression dilution ratio 
of loge GGT was 0.68 (95% CI: 0.61-0.74). After correction for within person variability, 
HR for AF was 1.06 (0.88-1.27). 7 
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DISCUSSION 
Finding a predictive biomarker for AF is important for clinical practice due to the 
morbidity and mortality resulting from AF complications. The two reviewed articles6,7 
suggest an elevation in serum GGT may predict the development of AF. Although the 
true magnitude of that risk is unknown as there is a lack of precision with the Kunutsor et 
al study7 and some inconsistency with the results as demonstrated by the HR in the 
Alonso et al study6 being significant (HR 1.44, 95% CI 1.17-1.77) while the other study7 
had a less significant HR (1.06, 95% CI 0.88-1.27). Additionally, Alonso et al6 included 
participants of the Atherosclerosis Risk in Communities (ARIC) cohort, which 
potentiates selection bias. In their investigation of AF, the population was exclusive to 
whites and blacks, and excluded any other ethnic groups. The KIHD study by Kunutsor et 
al7, was exclusive to middle-aged Finnish men. The exclusion of other ethnic groups and 
women shows a selection bias and fails to allow the results to be applied across various 
populations. Although the KIHD study has little loss to follow-up, the sample size of 
1780 participants was small. The retrospective nature of both of these studies may have 
underestimated AF cases due to numerous initial AF events having the ability to 
spontaneously resolve within the first 24 hours of onset.1 Specifically, the Kunutsor et al 
study7 did not delineate if AF was paroxysmal or treated by cardioversion due to data 
being obtained from hospital records. Due to these limitations, more studies would be 
warranted in order to solidify this correlation.  
The relation of AF and increased GGT level remains an area of further research. 
Tekin et al9 took interest in the correlation of both AF and GGT having an association 
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with systemic inflammation and oxidative stress and their study has shown that patients 
with chronic AF have an increase in serum GGT activity when compared to those without 
AF. The logistic regression analysis of this study portrayed that serum GGT activity was 
significantly and independently associated with AF. Additionally, GGT shows to be a 
possible marker to identify patients at risk for AF recurrence after catheter ablation.10 
This biomarker would prove helpful in identifying which individuals would be more 
likely to maintain normal sinus rhythm post-ablation. The link of elevated systemic GGT 
and AF remains an area where further studies area indicated.  
CONCLUSION 
 AF remains an important medical condition due to its prevalence and the 
increasing incidence with the aging population. The studies reviewed suggest serum GGT 
as a potential biomarker to predict the risk of AF development. The importance is 
exemplified due to the significant morbidity and mortality experienced by complications 
of individuals affected with AF. Further studies of the association of AF and serum GGT 
are advised. With insight of AF predictability, it could potentially guide researchers in the 
direction to better understand the etiology of AF, which remains currently undiscovered. 
This discovery is likely to dramatically decrease the high costs associated with the 
hospitalization of AF, AF-related complications, and maintenance therapy. Knowledge of 
the cause of AF could prove to be a monumental discovery in medicine and the 
improvement of the morbidity of those at risk for AF. 
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Table 1: Quality Assessment of Reviewed Articles 
Study Design 
Downgrade Criteria 
Upgrade Criteria Quality 
Limitations Indirectness Inconsistency Imprecision 
Publication 
bias 
Alonso et 
al1 
Observational Seriousa Not Serious Not Serious Not Serious Unlikely No residual 
confounders 
Very 
low 
Kunutsor et 
al2 
Observational  Seriousb Not Serious Not Serious Seriousc Unlikely No upgrade Very 
low 
a Limited participant inclusion criteria to the exclusion of other races beyond white and black 
b Only included middle-aged Finnish men from eastern Finland  
c Small sample size 
 
 
 
 
 
 
 
